• Search

Search in Site

PharmaDeviceNews | Pharma and Medical Device Industry News PharmaDeviceNews.com
  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
```
Home»Posts tagged with»REACH study

Could OM Pharma’s Broncho-Vaxom study change how clinicians assess recurrent RTI prevention?

By Pallavi Madhiraju on June 14, 2026   Pharma & Biotech  

Could OM Pharma’s Broncho-Vaxom study change how clinicians assess recurrent RTI prevention?

Find out how OM Pharma’s Broncho-Vaxom data could reshape RTI prevention, real-world evidence and non-antibiotic care strategies.

Recent Posts

  • AstraZeneca and YMCA target the overlooked barriers delaying cancer screening in America
  • AL-S Pharma’s AP-101 Phase 2 data strengthen the misfolded SOD1 strategy in ALS
  • Why the OSSIO and OrthoPediatrics deal could reshape pediatric orthopedic fixation
  • Could centanafadine reshape nonstimulant ADHD treatment after Otsuka’s Phase 3b success?
  • Agenus prepares ESMO GI 2026 survival update as BOT+BAL enters its Phase 3 test
  • Why Star Therapeutics’ complete VGA039 dataset matters for the future of von Willebrand disease care
  • Epicrispr’s one-time EPI-321 therapy shows early muscle growth after DUX4 silencing
  • Omeros’ TA-TMA therapy hits European hurdle as regulators question treatment effect
  • Shionogi deepens ALS real-world data strategy after $2.5bn Radicava acquisition
  • Incyte’s Opzelura wins positive CHMP opinion for moderate atopic dermatitis in Europe
  • Datroway nears EU first-line approval for metastatic triple-negative breast cancer
  • Acadia Pharmaceuticals secures positive CHMP opinion for Daybu in narrowed Rett syndrome indication
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes